Intelligence Brief — Life Sciences GTM
What moved in Life Sciences commercial markets this week. Named companies, specific numbers, and a play for each signal. Published Tuesday and Friday by MarlowIQ.
Illumina files 8-K disclosing entry into and termination of material definitive agreements — sequencing partnership map is being redrawn.
Illumina filed a Form 8-K with the SEC on August 13, 2026 disclosing entry into a material definitive agreement and termination of a material agreement. The filing lands into a quarter where Q3 2025 revenue was $1.08B, flat year over year on reported and constant currency, and instrument mix remains under pressure. The disclosure came the same week 10x Genomics announced the Proteintech Genomics acquisition and pulled high-plex protein multi-omics into the Atera roadmap. No public headline explanation from Illumina yet.
A terminated material agreement at Illumina, whether a supply, distribution, or co-development deal, reshapes who Illumina goes to market with next. Sequencing tools competitors, capital-equipment channel partners, and downstream informatics vendors need to know whether they are on the near side or far side of this change before Illumina explains it on the next call. First narrative to reach the customer wins the account conversation.
Sequencing tools competitors and downstream informatics vendors should identify the terminated counterparty within 48 hours of the filing and brief their top 20 sequencing accounts on the implication before Illumina frames it publicly. First narrative wins the customer conversation — waiting for the next earnings call means competing after Illumina has anchored the story.
IQVIA closes Charles River discovery asset purchase — CRO consolidation moves from announcement to booked revenue.
IQVIA reported Q2 2026 results confirming the acquisition of Charles River discovery assets closed during the quarter, contributing a 50 basis point uplift to full-year M&A revenue growth. Charles River's own Q2 print showed +0.1% organic and a sharp China revenue decline, with biologics and gene therapy carrying the result. The discovery asset divestiture routes historic CRL preclinical work into IQVIA's clinical-connected data platform. Fortrea beat Q2 estimates by $0.05 EPS but backlog coverage beyond one year at Medpace has now declined for six consecutive quarters.
The buy-side CRO consolidation is now recognised in revenue, not just announcement risk. Discovery-to-clinical handoffs at IQVIA-connected sponsors will be routed inside one contract structure. Specialty and mid-market CROs lose the seam they used to compete on, and preclinical-only providers face pricing pressure. Sponsors mid-RFP need to price the closed transaction into their vendor decisions this cycle.
Specialty CROs and preclinical service providers should re-engage every sponsor with an in-flight Q3 RFP this quarter and reprice against the integrated IQVIA discovery-to-clinical stack. The closed transaction changes the vendor math on active RFPs — waiting for the next cycle means competing after IQVIA has already anchored the sponsor's preclinical-to-clinical baseline.
mIQ (0–100): our composite score of how ready an account is to buy.
Three accounts moved in mIQ this week on confirmed procurement and pipeline signals.
Full access shows mIQ scores for all 970+ accounts and the ranked opportunity board.
5 signals this week — each with a named play and specific timing.
Full access: mIQ scores on 970+ accounts, active clinical trial pipeline, and every competitor baseline — updated weekly.
Request full access →3 more signals in this brief.
MarlowIQ is in private preview. Request access to read every signal and receive Tuesday and Friday briefs in your inbox.
By invitation — design partners only.
Go deeper on any signal — Ask Marlow →